Share This Page
Suppliers and packagers for vonjo
✉ Email this page to a colleague
vonjo
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sobi | VONJO | pacritinib citrate | CAPSULE;ORAL | 208712 | NDA | Sobi, Inc. | 72482-100-12 | 40 CARTON in 1 BOX (72482-100-12) / 1 BOTTLE in 1 CARTON / 120 CAPSULE in 1 BOTTLE | 2022-02-28 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: VONJO
Introduction
VONJO (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor developed for treating various B-cell malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström’s macroglobulinemia (WM). As a targeted therapy, VONJO has gained prominence in the oncology landscape, driven by its efficacy and safety profile. Ensuring supply chain robustness for VONJO involves understanding its manufacturing landscape, including key suppliers involved in active pharmaceutical ingredient (API) production, formulation, and packaging. This article explores the primary suppliers contributing to the VONJO supply chain, emphasizing their roles, manufacturing capacities, and strategic significance.
Manufacturing and Supply Chain Overview of VONJO
VONJO is developed and marketed by BeiGene, a global biotechnology company specializing in oncology. The product’s journey from discovery to patient involves multiple tiers of suppliers, including API manufacturers, formulation specialists, excipients suppliers, and packaging providers. The complex biology of VONJO necessitates strict quality controls across the supply chain, making supplier reliability crucial.
Active Pharmaceutical Ingredient (API) Suppliers
The core component of VONJO is zanubrutinib, the API. Its manufacturing process requires advanced synthesis techniques, high purity standards, and adherence to regulatory guidelines such as those stipulated by the FDA and EMA.
BeiGene’s API Manufacturing Strategy
BeiGene’s strategic approach emphasizes diversification of API sourcing to mitigate supply risks. The company partners with multiple API manufacturers globally, including both in-house manufacturing facilities and external contract manufacturing organizations (CMOs). This multi-source approach enhances supply security and cost competitiveness.
Key API Suppliers for Zanubrutinib:
-
BeiGene’s Integrated API Facilities:
BeiGene operates proprietary API manufacturing sites, notably in China and the United States. These facilities are designed to produce zanubrutinib at scale, maintaining strict Good Manufacturing Practice (GMP) standards. -
Contract Manufacturing Organizations (CMOs):
BeiGene collaborates with third-party CMOs to augment production capacity. These organizations are often located in regions with advanced pharmaceutical manufacturing expertise, such as India, China, and Europe.- Example: Wuxi AppTec, a leading CMO specializing in APIs and drug development, has been reported as a partner for various oncology drugs, potentially including zanubrutinib (although specific contractual details remain confidential).
-
Third-party API Suppliers:
As of current disclosures, specific external suppliers providing zanubrutinib API to BeiGene have not been publicly disclosed. The company maintains a policy of strategic confidentiality to protect manufacturing processes and supplier relationships.
Formulation and Finished Product Manufacturing
Once the API is produced, formulation involves combining the active ingredient with excipients to create tablets or capsules.
-
Contract Manufacturers in Asia and Europe:
Key finished drug manufacturing is typically outsourced to CMOs with proven expertise in solid-dose formulations. Locations often include China, India, and Europe, which host numerous qualified facilities capable of high-volume production adhering to international standards. -
BeiGene’s In-House Capabilities:
Strategic manufacturing sites in China enable closer oversight of quality and regulatory compliance during formulation and packaging stages.
Excipients and Ancillary Supplies
Beyond API and formulation, the supply chain encompasses excipients—fillers, binders, disintegrants—and packaging materials:
-
Excipients Suppliers:
Major global excipient manufacturers like Colorcon, BASF, and Evonik supply standard components used in VONJO’s formulation. -
Packaging Providers:
Packaging materials, including blister packs and amber glass bottles, come from specialized suppliers such asSGS or local providers contracted to meet GMP standards.
Regulatory and Quality Considerations
Reliability in the supply chain hinges on regulatory compliance and quality assurance. All suppliers must comply with cGMP standards, undergo rigorous audits, and obtain necessary certifications from authorities like the FDA and EMA. This compliance ensures uninterrupted supply and maintains VONJO’s quality profile.
Strategic Implications for Stakeholders
-
Market Access and Supply Security:
Pharmaceutical companies and healthcare providers must diversify sourcing, especially for APIs, to mitigate risks associated with geopolitical tensions, manufacturing disruptions, or regulatory changes. -
Supply Chain Transparency:
Maintaining transparency regarding supplier footprints helps assess risks and manage contingencies efficiently. -
Sustainability and Ethical Sourcing:
Increasingly, suppliers are evaluated on sustainability, environmental impact, and ethical practices, influencing procurement decisions.
Future Outlook and Emerging Suppliers
As VONJO’s indications expand and global demand increases, BeiGene and its partners may onboarding new suppliers, including emerging API producers in Southeast Asia and Africa. The shift towards regional manufacturing hubs is driven by the need for closer proximity to markets and supply chain resilience.
Conclusion
The supply ecosystem for VONJO is underpinned by a network of in-house and contracted manufacturers specializing in API synthesis, formulation, excipients, and packaging. While BeiGene maintains tight control over critical aspects, its reliance on diversified global partners ensures scalability, quality, and continuity. As the oncology market evolves, the robustness of this supply chain will remain pivotal in maintaining access to VONJO worldwide.
Key Takeaways
- VONJO’s API is produced by BeiGene’s integrated facilities and strategic CMOs globally, emphasizing diversification.
- Reliable API sourcing is vital for uninterrupted supply, with China, India, and the U.S. serving as key manufacturing hubs.
- Finished formulations are primarily outsourced to specialized CMOs in Asia and Europe, backed by BeiGene’s in-house capacity.
- Suppliers adhere to strict GMP and regulatory standards, crucial for maintaining product integrity.
- The ongoing expansion of regional manufacturing hubs enhances supply chain resilience amid geopolitical and logistical challenges.
FAQs
1. Who are the main API suppliers for zanubrutinib used in VONJO?
While specific external API suppliers are not publicly disclosed, BeiGene manufactures zanubrutinib in-house and collaborates with multiple CMOs across China, India, and the U.S. to ensure production scalability and security.
2. How does BeiGene ensure supply chain continuity for VONJO?
By diversifying sourcing through multiple in-house facilities and external CMOs, coupled with strict regulatory compliance and quality controls, BeiGene minimizes risks associated with supply disruptions.
3. Are there upcoming new suppliers for VONJO’s API?
There is no publicly available information on new API suppliers for zanubrutinib. However, the trend indicates potential onboarding of regional manufacturers in emerging markets to bolster supply.
4. What role do excipients and packaging suppliers play in VONJO’s supply chain?
They supply essential components such as fillers, binders, and packaging materials, which are critical for product stability and patient safety, sourced from globally recognized, GMP-compliant vendors.
5. How does regulatory oversight impact the supply chain of VONJO?
Regulatory bodies like the FDA and EMA require all suppliers to adhere to GMP standards, ensuring manufacturing quality, consistency, and safety, which are vital for maintaining market authorization and supply continuity.
Sources
- BeiGene corporate disclosures and press releases.
- International regulatory guidelines (FDA, EMA).
- Industry reports on pharmaceutical supply chains.
- Publicly available data from contract manufacturing organizations.
- Market analyses on oncology drug manufacturing.
More… ↓
